SAN DIEGO — Dapagliflozin provides significant benefits in the treatment of chronic kidney disease (CKD) even when initiated in patients with the most severe stages of the disease who are typically excluded from clinical trials, new research shows. In patients with CKD stage 4-5, dapagliflozin plus integrated CKD care improved total eGFR slope composite renal …
